Annovis Bio, Inc.(ANVS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ANVS Annovis Bio, Inc.

Market Closed 11-06 16:00:00 EST

0.8449

+0.1760

+26.31%

盘后0.9601

+0.1152+13.63%

19:59 EST

High0.8527	Low0.6301	Vol11.74M
Open0.7000	D1 Closing0.6689	Amplitude33.28%
Mkt Cap52.40M	Tradable Cap48.40M	Total Shares62.02M
T/O8.87M	T/O Rate20.48%	Tradable Shares57.29M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ANVS","market":"US","secType":"STK","nameCN":"Annovis Bio, Inc.","latestPrice":0.8449,"timestamp":1793998800000,"preClose":0.6689,"halted":0,"volume":11735883,"hourTrading":{"tag":"盘后","latestPrice":0.9601,"preClose":0.8449,"latestTime":"19:59 EST","volume":2801526,"amount":2691032.583142,"timestamp":1794013195973,"change":0.1152,"changeRate":0.136347,"amplitude":0.26271},"delay":0,"changeRate":0.2631185528479592,"floatShares":57290300,"shares":62022500,"eps":-1.789521,"marketStatus":"Market Closed","change":0.176,"latestTime":"11-06 16:00:00 EST","open":0.7,"high":0.8527,"low":0.6301,"amount":8869910.54289615,"amplitude":0.332785,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-1.789521,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1794214800000},"marketStatusCode":7,"adr":0,"listingDate":1580274000000,"exchange":"NYSE","adjPreClose":0.6689,"preHourTrading":{"tag":"盘前","latestPrice":0.6999,"preClose":0.6689,"latestTime":"09:29 EST","volume":74359,"amount":50766.37276205,"timestamp":1793975399098,"change":0.031,"changeRate":0.046345,"amplitude":0.046644},"postHourTrading":{"tag":"盘后","latestPrice":0.9601,"preClose":0.8449,"latestTime":"19:59 EST","volume":2801526,"amount":2691032.583142,"timestamp":1794013195973,"change":0.1152,"changeRate":0.136347,"amplitude":0.26271},"volumeRatio":1.565058,"impliedVol":1.2375,"impliedVolPercentile":0.6653},"requestUrl":"/m/hq/s/ANVS","defaultTab":"news","newsList":[{"id":"2681717894","title":"Annovis Bio Director Michael B Hoffman Reports $5 Million Common Share Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2681717894","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":1,"itemType":null,"share":"https://ttm.financial/m/news/2681717894?lang=en_us&edition=fundamental","pubTime":"2026-11-07 05:31","pubTimestamp":1794000706,"startTime":"0","endTime":"0","summary":"Annovis Bio Director Michael B Hoffman Reports $5 Million Common Share AcquisitionAnnovis Bio director Michael B. Hoffman purchased 5,000,000 shares of common stock, bringing his direct holdings to 8,","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261106:nNDL9j5Jzj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Annovis Bio Director Michael B Hoffman Reports $5 Million Common Share Acquisition","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ANVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681914889","title":"Annovis Bio Announces Pricing of Public Offering and Underwriting Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2681914889","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681914889?lang=en_us&edition=fundamental","pubTime":"2026-11-06 07:29","pubTimestamp":1793921363,"startTime":"0","endTime":"0","summary":"Annovis Bio ( ($ANVS) ) has issued an announcement. On November 4, 2026, Annovis Bio announced the launch of a public offering, and on November 5, ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/annovis-bio-announces-pricing-of-public-offering-and-underwriting-agreement?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/annovis-bio-announces-pricing-of-public-offering-and-underwriting-agreement?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ANVS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681079590","title":"Annovis Bio 21M share Spot Secondary priced at $1.00","url":"https://stock-news.laohu8.com/highlight/detail?id=2681079590","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681079590?lang=en_us&edition=fundamental","pubTime":"2026-11-05 22:01","pubTimestamp":1793887276,"startTime":"0","endTime":"0","summary":"Canaccord is acting as sole book running manager for the offering. The deal priced below last closing price of $1.21. Published first on TheFly – t...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/annovis-bio-21m-share-spot-secondary-priced-at-1-00-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/annovis-bio-21m-share-spot-secondary-priced-at-1-00-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ANVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681107617","title":"Annovis Bio Slumps on $21 Mln Stock Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2681107617","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681107617?lang=en_us&edition=fundamental","pubTime":"2026-11-05 21:47","pubTimestamp":1793886442,"startTime":"0","endTime":"0","summary":"BUZZ-Annovis Bio slumps on $21 mln stock sale** Annovis Bio'sANVS.Nshares slump 30% to record low of 85 cents premarket after $21 mln equity raise** Malvern, Pennsylvania-based biotech sells 21 mln shares including pre-funded warrants at $1** Offering price represents 17.4% discount to stock's last close** Co also issues accompanying warrants to purchase up to 21 mln shares; those 5-yr warrants are exercisable immediately at exercise price of $1** ANVS intends to use net offering proceeds for clinical development of its lead drug, buntanetap, in clinical studies for Alzheimer’s disease and Parkinson's disease, and for working capital and general purposes** Canaccord Genuity sole bookrunner** Co has ~43 mln shares outstanding as of Nov 3** Through Weds, shares shed 65% YTD** All 4 analysts covering the stock rate it \"buy\"; median PT $9, per LSEG data","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261105:nL6N46M11N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANVS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681073578","title":"Annovis Announces Pricing of $21.0 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2681073578","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681073578?lang=en_us&edition=fundamental","pubTime":"2026-11-05 21:05","pubTimestamp":1793883934,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261105:nTUA28RLDH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ANVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681785490","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2681785490","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681785490?lang=en_us&edition=fundamental","pubTime":"2026-11-05 20:45","pubTimestamp":1793882739,"startTime":"0","endTime":"0","summary":"MNTN  stock was 45% lower pre-bell Thursday after the company posted higher Q3 earnings and revenue.Veracyte  shares were down 29%, a day after the company reported its Q3 financial results.Annovis Bio  stock was 24% lower after the company announced a proposed underwritten public offering of common stock and warrants.Akebia Therapeutics  shares were down 26% after the company posted a Q3 loss amid lower revenue.BuzzFeed  stock was 24% lower following the company's Q3 financial results.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4587","VCYT","BZFD","BK4111","FBT","MNTN","ANVS","BK4009","AKBA","BK4077","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681310096","title":"Annovis Bio Files Charter Amendment After Stockholder Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2681310096","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681310096?lang=en_us&edition=fundamental","pubTime":"2026-11-05 05:57","pubTimestamp":1793829466,"startTime":"0","endTime":"0","summary":"Annovis Bio ( ($ANVS) ) just unveiled an update. On November 3, 2026, Annovis Bio stockholders approved increasing authorized common shares from 70...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/annovis-bio-files-charter-amendment-after-stockholder-approval?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/annovis-bio-files-charter-amendment-after-stockholder-approval?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LU0130103400.USD","LU0130517989.USD","LU0648001328.SGD","LU0477156953.USD","CHTR","LU0175139822.USD","BK4585","LU0320765489.SGD","LU0130518102.USD","ANVS","BK4559","LU1201861249.SGD","LU1201861165.SGD","LU0070302665.USD","LU0130102774.USD","LU0980610538.SGD","LU0477156797.USD","LU0289960550.SGD","LU0211331839.USD","BK4534","LU0208291251.USD","BK4588","BK4100","LU0648000940.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681093624","title":"Annovis Bio Launches Proposed Public Offering of Common Stock and Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2681093624","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681093624?lang=en_us&edition=fundamental","pubTime":"2026-11-05 05:33","pubTimestamp":1793828023,"startTime":"0","endTime":"0","summary":"Annovis Bio Launches Proposed Public Offering of Common Stock and WarrantsAnnovis Bio launched a proposed underwritten public offering of common stock or pre-funded warrants, with accompanying warrant","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nNDL2qVTW0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","SG9999014021.USD","BK4112","BCDF","IE00BKPKM429.USD","SG9999014005.SGD","SG9999014013.SGD","IE00BN0W2V16.EUR","NDAQ","LU0314104364.USD","IE00BN0W2T93.GBP","IE00BQXX3C00.GBP","ANVS","BK4588","IE00BQXX3D17.EUR","LU2210150020.SGD","IE00BQXX3F31.USD","IE00BN0W2W23.USD","BK4139","LU2210149790.SGD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","BK4585","SG9999014039.USD","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681982350","title":"Annovis Bio Holds Special Stockholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2681982350","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681982350?lang=en_us&edition=fundamental","pubTime":"2026-11-05 05:28","pubTimestamp":1793827706,"startTime":"0","endTime":"0","summary":"Annovis Bio Holds Special Stockholder MeetingAnnovis Bio shareholders approved increasing authorized Common Stock from 70,000,000 to 140,000,000 shares at the November 3, 2026, special meeting.The cha","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nNDL62V2h4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANVS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681606764","title":"Annovis Bio - to Use Net Proceeds for Buntanetap Development and Corporate Purposes","url":"https://stock-news.laohu8.com/highlight/detail?id=2681606764","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681606764?lang=en_us&edition=fundamental","pubTime":"2026-11-05 05:07","pubTimestamp":1793826420,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nTUA5KRV8N:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ANVS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681067936","title":"Annovis Bio - to Offer Shares, Pre-Funded Warrants, and Accompanying Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2681067936","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681067936?lang=en_us&edition=fundamental","pubTime":"2026-11-05 05:07","pubTimestamp":1793826420,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nTUA5KRV8N:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ANVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681067611","title":"Annovis Announces Launch of Proposed Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2681067611","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681067611?lang=en_us&edition=fundamental","pubTime":"2026-11-05 05:07","pubTimestamp":1793826420,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nTUA5KRV8N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ANVS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679240202","title":"Annovis Bio Receives NYSE Notice for Failing Continued Listing Standards","url":"https://stock-news.laohu8.com/highlight/detail?id=2679240202","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679240202?lang=en_us&edition=fundamental","pubTime":"2026-10-31 05:00","pubTimestamp":1793394049,"startTime":"0","endTime":"0","summary":"Annovis Bio Receives NYSE Notice for Failing Continued Listing StandardsAnnovis Bio received an NYSE noncompliance notice on October 29, 2026, for breaching market capitalization and stockholders' equ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261030:nNDL4g7Hy0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","BK4139","IE00BN0W2W23.USD","IE00BQXX3D17.EUR","BK4112","LU0314104364.USD","IE00BQXX3C00.GBP","LU2210150020.SGD","IE00BQXX3F31.USD","IE00BKPKM429.USD","IE00B64PRP62.GBP","ANVS","SG9999014039.USD","SG9999014021.USD","SG9999014013.SGD","IE00BN0W2T93.GBP","NDAQ","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","BK4585","LU2210149790.SGD","BK4588","LU2095319765.USD","BCDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679228436","title":"Annovis Bio, Inc. Receives Continued Listing Standard Notice from the NYSE","url":"https://stock-news.laohu8.com/highlight/detail?id=2679228436","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679228436?lang=en_us&edition=fundamental","pubTime":"2026-10-31 05:00","pubTimestamp":1793394000,"startTime":"0","endTime":"0","summary":"MALVERN, Pa., Oct.  30, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/30/3392667/0/en/annovis-bio-inc-receives-continued-listing-standard-notice-from-the-nyse.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AD","LU1169590202.USD","BK4023","ANVS","BK4124","PD","BK4132","BK4139","NYSE","LU1169589451.USD","SMP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679540149","title":"Annovis to Participate in U.S. Biotech Day 2026 and Pharma Partnering Summit 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2679540149","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679540149?lang=en_us&edition=fundamental","pubTime":"2026-10-29 20:00","pubTimestamp":1793275200,"startTime":"0","endTime":"0","summary":"Maria Maccecchini, PhD, CEO of Annovis, will join industry panel with pharma leaders and present company updatesMALVERN, Pa., Oct.  29, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovi","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/29/3391187/0/en/annovis-to-participate-in-u-s-biotech-day-2026-and-pharma-partnering-summit-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PD","LU1169589451.USD","BK4588","LU1169590202.USD","XBI","ANVS","BK4132","AD","BK4581","BK4585","BK4023"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677097441","title":"Annovis Bio: Buy Rating Reiterated as Buntanetap Nears Key Alzheimer’s Phase 3 and CTAD Milestones; Price Target Maintained at $8","url":"https://stock-news.laohu8.com/highlight/detail?id=2677097441","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677097441?lang=en_us&edition=fundamental","pubTime":"2026-10-24 03:15","pubTimestamp":1792782928,"startTime":"0","endTime":"0","summary":"Analyst Jason McCarthy from Maxim Group maintained a Buy rating on Annovis Bio and keeping the price target at $8.00. Jason McCarthy has given his ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/annovis-bio-buy-rating-reiterated-as-buntanetap-nears-key-alzheimers-phase-3-and-ctad-milestones-price-target-maintained-at-8-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/annovis-bio-buy-rating-reiterated-as-buntanetap-nears-key-alzheimers-phase-3-and-ctad-milestones-price-target-maintained-at-8-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ANVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677916968","title":"Annovis Bio Plans Three Presentations at CTAD Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2677916968","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677916968?lang=en_us&edition=fundamental","pubTime":"2026-10-22 20:10","pubTimestamp":1792671023,"startTime":"0","endTime":"0","summary":"Annovis Bio Plans Three Presentations at CTAD ConferenceAnnovis Bio will deliver three presentations at the Clinical Trials on Alzheimer's Disease conference in Boston, Nov. 16-19, 2026.An oral presen","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261022:nNDL1dh9Q8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","IE00BN0W2W23.USD","BK4588","BCDF","LU2210150020.SGD","IE00BQXX3D17.EUR","BK4139","IE00BQXX3F31.USD","SG9999014005.SGD","BK4112","IE00BGHQF748.EUR","IE00BN0W2V16.EUR","BK4585","SG9999014021.USD","IE00BQXX3C00.GBP","IE00BN0W2T93.GBP","SG9999014039.USD","LU2095319765.USD","LU0314104364.USD","LU2210149790.SGD","ANVS","NDAQ","IE00B64PRP62.GBP","IE00BKPKM429.USD","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676664879","title":"Annovis Bio Corrects 2025 Audit Fees to $415,000 After Proxy Typo","url":"https://stock-news.laohu8.com/highlight/detail?id=2676664879","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676664879?lang=en_us&edition=fundamental","pubTime":"2026-10-20 18:04","pubTimestamp":1792490663,"startTime":"0","endTime":"0","summary":"Annovis Bio Corrects 2025 Audit Fees to $415,000 After Proxy TypoAnnovis Bio corrected audit fee disclosures following a typographical error in its proxy for the June 17, 2026, annual meeting.Total fe","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261020:nNDL9hcD9d:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ANVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669375485","title":"Annovis Bio announces partnership with Weave Bio","url":"https://stock-news.laohu8.com/highlight/detail?id=2669375485","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669375485?lang=en_us&edition=fundamental","pubTime":"2026-09-23 20:10","pubTimestamp":1790165409,"startTime":"0","endTime":"0","summary":"Annovis Bio (ANVS) announced a collaboration with Weave Bio, an AI platform for regulatory content and knowledge management, in support of the plan...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/annovis-bio-announces-partnership-with-weave-bio-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/annovis-bio-announces-partnership-with-weave-bio-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","VTHR","AIPO","AGIX","QTOC","ANVS","CHAT","ARTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669839794","title":"Annovis Announces Partnership with Weave Bio, AI Regulatory Platform, in Preparation of Nda for Buntanetap in Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2669839794","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669839794?lang=en_us&edition=fundamental","pubTime":"2026-09-23 20:00","pubTimestamp":1790164801,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nTUA4Y24L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ANVS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.annovisbio.com","stockEarnings":[{"period":"1week","weight":-0.3442},{"period":"1month","weight":-0.4331},{"period":"3month","weight":-0.6442},{"period":"6month","weight":-0.7066},{"period":"1year","weight":-0.6721},{"period":"ytd","weight":-0.8067}],"compareEarnings":[{"period":"1week","weight":-0.027},{"period":"1month","weight":-0.0539},{"period":"3month","weight":-0.0491},{"period":"6month","weight":-0.0032},{"period":"1year","weight":0.0969},{"period":"ytd","weight":0.0783}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.040659},{"month":2,"riseRate":0.285714,"avgChangeRate":0.058949},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.056117},{"month":4,"riseRate":0.142857,"avgChangeRate":-0.132244},{"month":5,"riseRate":0.571429,"avgChangeRate":0.255652},{"month":6,"riseRate":0.428571,"avgChangeRate":0.139284},{"month":7,"riseRate":0.571429,"avgChangeRate":0.075716},{"month":8,"riseRate":0.285714,"avgChangeRate":-0.062756},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.087505},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.078357},{"month":11,"riseRate":0.571429,"avgChangeRate":0.171618},{"month":12,"riseRate":0.333333,"avgChangeRate":0.124011}],"exchange":"NYSE","name":"Annovis Bio, Inc.","nameEN":"Annovis Bio, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Annovis Bio, Inc.(ANVS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Annovis Bio, Inc.(ANVS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Annovis Bio, Inc.,ANVS,Annovis Bio, Inc.股票,Annovis Bio, Inc.股票老虎,Annovis Bio, Inc.股票老虎国际,Annovis Bio, Inc.行情,Annovis Bio, Inc.股票行情,Annovis Bio, Inc.股价,Annovis Bio, Inc.股市,Annovis Bio, Inc.股票价格,Annovis Bio, Inc.股票交易,Annovis Bio, Inc.股票购买,Annovis Bio, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Annovis Bio, Inc.(ANVS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Annovis Bio, Inc.(ANVS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}